ReviewHeart failure reviews2010
Genetic variation in the natriuretic peptide system and heart failure.
Review in Heart failure reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Structural insights into single-pass transmembrane receptor GC-A activation by distinct antihypertensive antibodies.Nature communications · 2026Article
- Mutational single nucleotide polymorphism rs198389 and demethylation promoted natriuretic peptide B gene transcription in heart failure caused by dilated cardiomyopathy.Genes & diseases · 2025Article
- The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes.Journal of clinical medicine · 2024Review
- Article
- Racial and ethnic differences in circulating N-terminal pro-brain-type natriuretic peptide (NT-proBNP) in US adults.American journal of preventive cardiology · 2023Article
- Pre-Conditioning Stem Cells in a Biomimetic Environment for Enhanced Cardiac Tissue Repair:Cellular and molecular bioengineering · 2018Article
- Pharmacogenomics of the Natriuretic Peptide System in Heart Failure.Current heart failure reports · 2017Review
- Molecular Characterization of Pediatric Restrictive Cardiomyopathy from Integrative Genomics.Scientific reports · 2017Article
- Genetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients.Journal of cardiovascular translational research · 2015Article
- Harnessing fetal and adult genetic reprograming for therapy of heart disease.Journal of nature and science · 2015Article
- Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide.Journal of cardiac failure · 2014Article
- Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway.Journal of cardiovascular translational research · 2013Article
- Weighted gene coexpression network analysis of human left atrial tissue identifies gene modules associated with atrial fibrillation.Circulation. Cardiovascular genetics · 2013Article
- Systems biology and biomechanical model of heart failure.Current cardiology reviews · 2012Review
- Natriuretic peptides in therapy for decompensated heart failure.European journal of clinical pharmacology · 2012Review
- Systems biology and heart failure: concepts, methods, and potential research applications.Heart failure reviews · 2010Review
- Progress toward genetic tailoring of heart failure therapy.Current opinion in molecular therapeutics · 2010Review
- Myocardial adaptations in the failing heart: cause or consequence?Journal of muscle research and cell motility · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Heart failure (HF) is a modern epidemic and is one of the few cardiovascular diseases which is increasing in prevalence. The growing importance of the Natriuretic Peptide (NP) system in HF is well recognized. Laboratory tests for B-type Natriuretic Peptide (BNP) have proven value as diagnostic and prognostic tools in HF and are now part of routine clinical care. Furthermore, recombinant atrial natriuretic peptide (ANP) (carperitide) and BNP (nesiritide) and are approved HF therapies in Japan and the US, respectively and additional natriuretic peptides (e.g., CNP, urodilatin, and designer NPs) are under investigation for use in HF. Common genetic sequence variants are increasingly being recognized as determinants of disease risk or drug response and may help explain a portion of the inter-individual variation in the human NP system. This review describes current knowledge of NP system genetic variation as it pertains to HF as well as ongoing studies and where the field is expected to progress in the near future. To briefly summarize, NP system genetic variants have been associated with alterations in gene expression, NP levels, and cardiovascular disease. The next step forward will include specific investigations into how this genetic variation can advance 'Personalized Medicine', such as whether they impact the utility of diagnostic BNP testing or effectiveness of therapeutic NP infusion. This is already in progress, with pharmacogenetic studies of nesiritide currently underway. We expect that within 5 years there should be a reasonable idea of whether NP system genetic variation will have important clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.